Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 tri...
Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial
About this item
Full title
Author / Creator
Miller, Jeffrey S. , Davis, Zachary B. , Helgeson, Erika , Reilly, Cavan , Thorkelson, Ann , Anderson, Jodi , Lima, Noemia S. , Jorstad, Siri , Hart, Geoffrey T. , Lee, John H. , Safrit, Jeffrey T. , Wong, Hing , Cooley, Sarah , Gharu, Lavina , Chung, Hyunsoo , Soon-Shiong, Patrick , Dobrowolski, Curtis , Fletcher, Courtney V. , Karn, Jonathan , Douek, Daniel C. and Schacker, Timothy W.
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
There is no cure for HIV infection, and lifelong antiretroviral therapy (ART) is required. N-803 is an IL-15 superagonist comprised of an N72D mutant IL-15 molecule attached to its alpha receptor and a human IgG1 fragment designed to increase IL-15 activity. Preclinical studies with both HIV and SIV suggest that the drug has potential to reduce vir...
Alternative Titles
Full title
Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial
Authors, Artists and Contributors
Author / Creator
Davis, Zachary B.
Helgeson, Erika
Reilly, Cavan
Thorkelson, Ann
Anderson, Jodi
Lima, Noemia S.
Jorstad, Siri
Hart, Geoffrey T.
Lee, John H.
Safrit, Jeffrey T.
Wong, Hing
Cooley, Sarah
Gharu, Lavina
Chung, Hyunsoo
Soon-Shiong, Patrick
Dobrowolski, Curtis
Fletcher, Courtney V.
Karn, Jonathan
Douek, Daniel C.
Schacker, Timothy W.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2624657587
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2624657587
Other Identifiers
ISSN
1078-8956
E-ISSN
1546-170X
DOI
10.1038/s41591-021-01651-9
